Stay updated on Immunotherapy in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy in NSCLC Clinical Trial page.

Latest updates to the Immunotherapy in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe ARC-7 study record for immunotherapies in PD-L1-positive non-small cell lung cancer is displayed, with trial design, participation criteria, outcomes, and study locations. It also includes information on sharing participant data and related study documents.SummaryDifference70%

- Check16 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check23 days agoChange DetectedA sitewide NIH notice links to transition updates and FAQs and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check37 days agoChange DetectedThe ClinicalTrials.gov footer now identifies the site as revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check50 days agoChange DetectedThe 403 error page and its Home link were removed, enabling the study details page to display its content again.SummaryDifference0.5%

Stay in the know with updates to Immunotherapy in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy in NSCLC Clinical Trial page.